Bvf Inc decreased Chemocentryx Inc (CCXI) stake by 1.27% reported in 2018Q4 SEC filing. Bvf Inc sold 86,237 shares as Chemocentryx Inc (CCXI)’s stock rose 6.99%. The Bvf Inc holds 6.69M shares with $72.96M value, down from 6.77 million last quarter. Chemocentryx Inc now has $530.95 million valuation. The stock decreased 6.31% or $0.68 during the last trading session, reaching $10.1. About 461,536 shares traded or 45.80% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 14, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18
Analysts expect Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report $-0.42 EPS on April, 1.They anticipate $0.60 EPS change or 58.82% from last quarter’s $-1.02 EPS. After having $-0.66 EPS previously, Titan Pharmaceuticals, Inc.’s analysts see -36.36% EPS growth. The stock decreased 3.89% or $0.07 during the last trading session, reaching $1.73. About 1,038 shares traded. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has declined 70.03% since March 14, 2018 and is downtrending. It has underperformed by 74.40% the S&P500. Some Historical TTNP News: 19/03/2018 SORICIMED ANNOUNCES THE APPOINTMENT OF DR. MARC RUBIN AND MR. VAUGHN EMBRO-PANTALONY TO BOARD OF DIRECTORS; 20/04/2018 – Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE(TM) for Opioid Drug Dependence; 21/03/2018 – TITAN GETS INITIAL EU2M PAYMENT, MAY GET ADDTL EU4.5M; 30/05/2018 – Titan Pharmaceuticals to Regain All Rights to Commercialization and Clinical Development of Probuphine in U.S. and Canada; 21/03/2018 – Titan Executes Agreement for Acquisition by Molteni of Probuphine in Europe and Other Select Territories; 21/03/2018 – TITAN EXECUTES PACT FOR PURCHASE BY MOLTENI OF PROBUPHINE® IN E; 21/03/2018 – Titan Pharmaceuticals Gets Initial Payment of About $2.4 Million for Assets; 02/04/2018 – Titan Pharmaceuticals 4Q Loss/Shr 17c; 30/05/2018 – Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence; 30/05/2018 – Titan Pharmaceuticals and Braeburn Announce Mutual Termination of License Agreement for Probuphine(R) for Opioid Dependence
More notable recent Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) news were published by: Seekingalpha.com which released: “Titan Pharmaceuticals teams up with AllianceRX Walgreens Prime; shares up 65% premarket – Seeking Alpha” on February 25, 2019, also Nasdaq.com with their article: “Mid-Day Market Update: Crude Oil Down 2.5%; Titan Pharmaceuticals Shares Spike Higher – Nasdaq” published on February 25, 2019, Seekingalpha.com published: “GE, DHR, SGMO among premarket gainers – Seeking Alpha” on February 25, 2019. More interesting news about Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) were released by: Benzinga.com and their article: “72 Biggest Movers From Yesterday – Benzinga” published on February 26, 2019 as well as Seekingalpha.com‘s news article titled: “Spark Therapeutics leads healthcare gainers; Achieve Life Sciences and Cronos Group among losers – Seeking Alpha” with publication date: February 25, 2019.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company has market cap of $22.48 million. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. It currently has negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It worsened, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Moreover, Metropolitan Life Ins New York has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 8,804 shares. Citadel Limited stated it has 19,773 shares. Blackrock holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.73 million shares. Sg Americas Securities Limited Com invested in 0% or 17,971 shares. Millennium Mgmt Lc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Wells Fargo Co Mn accumulated 67,539 shares. Barclays Public Limited Co reported 5,866 shares stake. Alps Advsrs Incorporated holds 0.01% or 156,559 shares in its portfolio. Franklin Resources reported 0.01% stake. Maryland-based Proshare Advsr has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Vanguard Group has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.36M shares. Adams Diversified Equity Fund Inc reported 38,600 shares. Renaissance Technologies Lc has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). 35,245 are held by California State Teachers Retirement. Dorsey Wright Associate holds 0% or 1,170 shares in its portfolio.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also Nasdaq.com with their article: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” published on March 11, 2019, Nasdaq.com published: “ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” published on February 26, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018.
Bvf Inc increased Molecular Templates Inc stake by 576,792 shares to 3.36M valued at $13.59 million in 2018Q4. It also upped Ac Immune Sa stake by 212,527 shares and now owns 2.23M shares. Merus N V was raised too.
Since October 16, 2018, it had 0 insider buys, and 8 insider sales for $87.64 million activity. Cappel Markus J. also sold $74,079 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Thursday, January 10. 7,211 shares were sold by Schall Thomas J., worth $86,554. Another trade for 37,893 shares valued at $457,747 was made by KANAYA SUSAN M on Tuesday, January 22. GLAXOSMITHKLINE PLC sold $85.85M worth of stock or 7.34 million shares.